The U.S. Food and Drug Administration (FDA) has granted its fast track designation to Reata Pharmaceuticals’ oral candidate omaveloxolone for Friedreich’s ataxia (FA).
Source:- Reata Pharmaceuticals
The prevalence and incidence of cases of Friedreich’s ataxia vary worldwide considering, ranging from 0.97 to 2.5 cases per 100,000 in the USA and approximately 1.2 to 2.37 cases per 100,000 population in Europe. Germany is the leading country among EU region in terms of total diagnosed and prevalent cases of Friedreich’s ataxia. Friedreich’s ataxia appears to be an ultra-rare disease reported globally. The population incidence of a person is homozygous for a point mutation is expected to be approximately 1 in 1,000,000 population.
Comprehensive insight on patient segmentation based on age, sex, Genotype, phenotype, Signs & Symptoms (LOFA & VLOFA) (Atypical & typical), Comorbid conditions (Cardiac problems, Visual problems, Auditory problems, Speech disorder, Swallowing disorder, Cognitive disorder, Deformities and fracture, Neurogenic bladder), severity (Mild, Moderate & Severe) has been provided into the epidemiology (Incidence and Prevalence) section of the Friedreich’s Ataxia and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China
In terms of pharmacologic therapies, Several drug candidates are in Phase II and I/II/ III stages of development by various companies. Key assets among these are, Omaveloxolone; Reata Pharm, MIN-102; Minoryx Therapeutics, SLS-005; Seelos Therapeutics, Epicatechin; Cardero Therapeutics, Horizon Pharma; Interferon ?-1b, RT001; Retrotope, Inc., debenone; Santhera Pharmaceuticals, EPI-743; Edison Pharmaceuticals, VP20629; Shire, LuAA24493; Lundbeck A/C, Among these key assets, some of the assets are being designated as an orphan drug from EMA and US FDA. The launch of key assets will positively impact the overall market from 2020 to 2030 in 8 MM countries.
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,